TCR Vβ use by T-cell clones found in the 13 patients studied and by Sézary cell lines
. | T-cell clones defined by immunoscopy . | . | Expanded T-cell clones phenotypically characterized . | . | . | |||
---|---|---|---|---|---|---|---|---|
TCR Vβ family . | PBMC, 13 patients . | Skin, 3 patients . | Malignant + SCLs . | Nonmalignant . | Total . | |||
1 | 0 | 0 | 0 | 0 | 0 | |||
2 | 1 | 1 | 1 | 0 | 1 | |||
3 | 3 | 0 | 0 | 0 | 0 | |||
4 | 1 | 0 | 0 | 0 | 0 | |||
5 | 2 | 0 | 0 | 0 | 0 | |||
6 | 1 | 0 | 0 | 0 | 0 | |||
7 | 1 | 0 | 1 | 0 | 1 | |||
8 | 2 | 1 | 2 | 0 | 2 | |||
9 | 0 | 0 | 0 | 0 | 0 | |||
11 | 1 | 0 | 1 | 0 | 1 | |||
12 | 0 | 0 | 0 | 0 | 0 | |||
13 | 1 | 0 | 1 | 0 | 1 | |||
14 | 2 | 0 | 0 | 2 | 2 | |||
15 | 2 | 1 | 0 | 0 | 0 | |||
16 | 1 | 1 | 0 | 0 | 0 | |||
17 | 4 | 1 | 1 | 1 | 2 | |||
18 | 1 | 0 | 0 | 0 | 0 | |||
20 | 1 | 0 | 0 | 0 | 0 | |||
21 | 1 | 0 | 0 | 0 | 0 | |||
22 | 2 | 0 | 1 | 2 | 3 | |||
23 | 2 | 0 | 1 | 0 | 1 | |||
24 | 0 | 0 | 0 | 0 | 0 | |||
Total | 28 | 5 | 9 | 5 | 14 |
. | T-cell clones defined by immunoscopy . | . | Expanded T-cell clones phenotypically characterized . | . | . | |||
---|---|---|---|---|---|---|---|---|
TCR Vβ family . | PBMC, 13 patients . | Skin, 3 patients . | Malignant + SCLs . | Nonmalignant . | Total . | |||
1 | 0 | 0 | 0 | 0 | 0 | |||
2 | 1 | 1 | 1 | 0 | 1 | |||
3 | 3 | 0 | 0 | 0 | 0 | |||
4 | 1 | 0 | 0 | 0 | 0 | |||
5 | 2 | 0 | 0 | 0 | 0 | |||
6 | 1 | 0 | 0 | 0 | 0 | |||
7 | 1 | 0 | 1 | 0 | 1 | |||
8 | 2 | 1 | 2 | 0 | 2 | |||
9 | 0 | 0 | 0 | 0 | 0 | |||
11 | 1 | 0 | 1 | 0 | 1 | |||
12 | 0 | 0 | 0 | 0 | 0 | |||
13 | 1 | 0 | 1 | 0 | 1 | |||
14 | 2 | 0 | 0 | 2 | 2 | |||
15 | 2 | 1 | 0 | 0 | 0 | |||
16 | 1 | 1 | 0 | 0 | 0 | |||
17 | 4 | 1 | 1 | 1 | 2 | |||
18 | 1 | 0 | 0 | 0 | 0 | |||
20 | 1 | 0 | 0 | 0 | 0 | |||
21 | 1 | 0 | 0 | 0 | 0 | |||
22 | 2 | 0 | 1 | 2 | 3 | |||
23 | 2 | 0 | 1 | 0 | 1 | |||
24 | 0 | 0 | 0 | 0 | 0 | |||
Total | 28 | 5 | 9 | 5 | 14 |
Phenotypic characterization of expanded T-cell clones relies on TCR Vβ, CD 158k, and cell-surface VIM expression. For PBMCs, n = 13 patients; for skin, n = 3.
SCLs indicates Sézary cell lines (HUT78 and Pno).